Clinical and Molecular Biology of Angiosarcoma by N.J. Andersen et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
9 
Clinical and Molecular Biology  
of Angiosarcoma 
N.J. Andersen1, R.E. Froman1, B.E. Kitchell2 and N.S. Duesbery1 
1Laboratory of Cancer and Developmental Cell Biology, Van Andel Research Institute 
Grand Rapids,  
2College of Veterinary Medicine, Michigan State University East Lansing, Michigan,  
USA 
1. Introduction 
‘Skepticism is a healthy response to diagnosis of any tumor as angiosarcoma. ‘ (Lane, 1952)  
Angiosarcoma (AS) is an aggressive malignancy of vascular tissue or vessel forming cells 
(Requena & Sangueza 1998). AS is rare in humans, making up 1-2 % of soft-tissue sarcomas 
(Young et al. 2010) and having an estimated incidence of 0.2/100,000 persons per year. 
Although AS can present anywhere in the body, in humans they typically arise in the skin 
or superficial soft tissues. It is most frequently noted on the face and scalp of elderly men 
where their persistent growth causes ulceration and infection, as well as on breasts, and 
extremities (Brennan et al. 2001; Fayette et al. 2007; Glazebrook et al. 2008). Less frequently 
AS arises in liver, heart, and spleen (Young et al. 2010). The literature is replete with 
retrospective analyses and case studies on AS but the rarity of patients diagnosed with this 
disease makes it difficult to perform more than a superficial investigation on the biology and 
clinical behavior of AS. However, the occurrence of AS is not restricted to humans and there 
are several alternative animal models with the potential to inform human studies. We have 
written this review to collect, compare, and contrast diverse reports on the biology and 
treatment of AS in humans and alternative animal models. Our objective is to establish a 
comparative framework to focus further discussion and scientific enquiry. 
2. Types of AS 
While there is general agreement angiosarcomas arise from endothelial cells, its causes are 
uncertain. There appears to be no single cause of AS in humans; rather, a variety of factors 
have been reported to contribute to risk of disease. Broadly speaking the causes of this 
disease may be classified as environmental, familial, and iatrogenic. 
2.1 Environmental AS 
Chronic exposure to any of several environmental risk factors has been linked with AS. Each 
of these directly or indirectly induce genetic mutations and alter gene expression. Vinyl 
chloride was first identified as an AS inducing compound when it was noticed that 
industrial plastic and synthetic rubber manufacturers as well as beauty salon personnel had 
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an elevated incidence of AS. Exposure to vinyl chloride was the only common element 
identified in both populations (Creech & Johnson 1974; Infante et al. 2009; Sahmel et al. 
2009). Vinyl chloride was used for the production of industrial resins and as a hairspray 
propellant. Interestingly, vinyl chloride increases the rate of hepatic AS because vinyl 
chloride is a carcinogen that is predominantly directed towards hepatic endothelial cells. 
The metabolism of vinyl chloride produces reactive metabolites that form pro-mutagenic 
DNA adducts (reviewed by Bolt (2005)).  
Chronic exposure to arsenic in pesticides or in a traditional medicinal tonic (Fowler’s 
solution) has also been linked to hepatic AS (Centeno et al. 2002; Falk et al. 1993). The 
precise mechanism(s) of arsenic carcinogenesis is uncertain, although it appears to act in an 
epigenetic fashion rather than as a classical mutagen, causing pleiotropic cellular effects that 
promote tumorigenesis (reviewed by Flora (2011)). 
No link between AS and UV exposure has been documented. However, there are published 
case reports of xeroderma pigmentosum patients developing cutaneous AS. Xeroderma 
pigmentosum is a rare autosomal recessive disease causing defects in nucleotide excision 
repair; the patients are sensitive to UV radiation and are at higher risk for developing skin 
cancers (de Boer & Hoeijmakers 2000; Kraemer et al. 1987). Whereas cutaneous AS normally 
develops in older patients with a mean onset of 63 years (Aust et al. 1997), cutaneous AS in 
xeroderma pigmentosum patients appears to have an earlier onset, ranging from 13 to 40 
years with a mean of 19.2 years (Arlett et al. 2006; Arora et al. 2008; Ludolph-Hauser et al. 
2000; Marcon et al. 2004; van Geel & den Bakker 2009). Further work is needed to establish 
whether there is a role for UV as a causative agent of cutaneous AS. 
2.2 Iatrogenic AS 
There are several examples of AS being induced as a consequence of prior medical 
treatment. Exposure to Thorotrast® (colloidal thorium-232 dioxide) has been linked to 
hepatic AS. Thorotrast® was used in the United States from the 1930’s through the 1960’s as 
a radiographic contrast compound to visualize blood vessels. Upon injection, Thorotrast is 
absorbed by bones, liver, spleen, and lymph nodes where it has a high bioavailability and 
releases alpha particles for imaging. While useful as an imaging agent, Thorotrast® was 
found to have unanticipated toxicities. Because it has a long biological half-life, patients 
were exposed to high levels of ionizing radiation for extended (lifelong) periods (Autenrieth 
& Lange 1979; Kiyosawa et al. 1989). Thorotrast® exposure has also been associated with 
increased risk of other cancers including hepatic ductal carcinoma and leukemia (Johnson et 
al. 1977; Looney 1960). 
Radiotherapy is an infrequent but well-recognized risk factor for AS (Botros et al. 2009; Fury 
et al. 2005; Miura et al. 2003). A study of 274,572 breast cancer patients in the SEER Cancer 
Incidence Public-Use Database (Yap et al. 2002) found that incidence of a subsequent 
sarcoma while low, was modestly elevated in patients receiving breast irradiation compared 
to patients not receiving such therapy (87/82,296 [0.0011%] versus 176/192,276 [0.0009%] 
respectively). Further, whereas AS accounted for approximately 6% of subsequent sarcomas 
in unirradiated patients, it represented almost 60% of cases within a previously irradiated 
field (Yap et al. 2002). It seems radiation therapy not only increases the incidence of 
secondary malignancies but also changes the spectrum of tumors associated with treatment. 
These results were consistent with a prior study using the same SEER database that showed 
increased incidence of AS in irradiated breast cancer patients versus unirradiated patients 
(Huang & Mackillop 2001).  
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However, a recent retrospective study of Finnish cancer patients showed different results 
(Virtanen et al. 2007). Surveying more than 300,000 cancer patient records accrued over a 50-
year period, Virtanen et al. (2007) failed to identify a statistically significant association of 
AS with prior radiation treatment. These results agree with an earlier Swedish study of 
122,991 women with breast cancer that showed no statistically significant correlation 
between radiation therapy and angiosarcoma, although they did observe a correlation with 
lymphedema (Karlsson et al. 1998). The Finnish research team did note a five-fold increase 
in AS among women with breast or gynecologic cancers when compared with the rest of the 
population. However, while the SEER-based studies focused on the incidence of subsequent 
sarcoma within the irradiated field of women with breast cancer, the Finnish study 
examined incidence irrespective of radiation field within a mixed population of men and 
women treated for several tumor diagnoses. Thus, the latter studies may have failed to 
demonstrate a statistically significant association between AS and radiotherapy because 
they were underpowered. 
Chronic lymphedema is another risk factor for AS. The most well known form is Stewart-
Treves syndrome, in which lymphedema presents in the adjacent arm after radical 
mastectomy (Stewart & Treves 1948). Although rare, AS is also associated with other chronic 
lymphedema disorders such as Milroy disease and elephantiasis (Hallel-Halevy et al. 1999; 
Offori et al. 1993). It is not immediately apparent why failure of lymph node drainage 
should promote AS. One possibility is that edema restricts perfusion and induces an 
ischemic response involving endothelial proliferation. If this were the case one might expect 
to see increased incidence of AS in association with peripheral arterial disease. However, 
such an association has not been reported. Alternatively, edema-mediated changes may 
create a permissive microenvironment allowing phenotypic expression of an otherwise 
masked trait that promotes endothelial proliferation. 
2.3 Familial AS 
Although patients with Von Hippel-Lindau disease show increased incidence of cranial 
hemangioblastoma (Kaelin 2007), no highly penetrant, causal mutation for AS in humans 
has been reported. This should not be interpreted as an indication that hereditary factors do 
not influence the risk of developing AS, but that the incidence of AS is so low that 
identifying such genetic factors may be exceedingly difficult. However, indirect evidence 
supports a role for hereditary factors in the onset or progression of AS. The incidence of all 
vascular tumors appears to be increased in offspring whose parents were diagnosed with 
kidney cancer, nervous system hemangioma, or hemangioblastoma, and AS of the trunk 
and extremities has been associated with maternal breast cancer (Ji & Hemminki 2007). 
Moreover, there is strong evidence for breed and strain-specific predisposition of AS in mice 
and dogs (see below). 
3. Clinical features 
3.1 Presentation 
The presentation of AS is tied to the site of occurrence. In cutaneous AS, tumor may begin as 
a bruise-like bluish coloration or a red nodular rash (Lane 1952; Morgan et al. 2004). It can 
also present as purplish multicentric lesions as seen in Stewart-Treves syndrome (Stewart & 
Treves 1948). Unfortunately due to the innocuous appearance of the initial dermal lesion, a 
large percentage of patients initially disregard the lesion and as a consequence have 
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systemic disease at the time of ultimate diagnosis (Morgan et al. 2004). For visceral and 
cardiac disease, AS most often presents as organ failure. Cardiac AS patients commonly 
have atrial fibrillation, malaise, and resting tachycardia (Ge et al. 2011; Matzke et al.). 
Splenic AS presents with splenomegaly (enlarged spleen) or abdominal pain and fatigue 
from splenic rupture (Falk et al. 1993); these patients may also have cytopenia, leukocytosis, 
and thrombocytosis. Hepatic AS patients initially present with jaundice and may also 
experience abdominal pain and fatigue (Mahony et al. 1982; Valenzuela et al. 2009). 
3.2 Diagnostic pathology 
There are two subtypes of angiosarcoma defined by pathology. Angiosarcoma is classically 
defined by a growth of spindle-shaped endothelial cells (Figure 1). In 1982, Weiss and 
Enzinger described a new subtype, epithelioid AS, with large rounded or polygonal cells 
that have an epithelial-like morphology (Weiss & Enzinger 1982). In reality, most tumors 
have a mixture of both spindle and round endothelial cells (Morgan et al. 2004). 
Angiosarcoma tumors classically consist of sheets of endothelial cells with multiple irregular 
anastomosing channels. These channels can be perfused and blood-filled or void and can be 
lined with a single or multiple layers of atypical endothelial cells (Koch et al. 2008; Ohsawa 
et al. 1995; Yang et al. 2010). Areas of hemorrhage and necrosis are also common in AS 
(Armah et al. 2007; Ge et al. 2011; Gong et al. 2011; Neuhauser et al. 2000; Ohsawa et al. 1995; 
Yang et al. 2010). Low grade lesions display irregular vascular channels lined with atypical 
endothelial cells in single or multiple layers (Koch et al. 2008). High-grade lesions are 
comprised of sheets of undifferentiated, pleomorphic cells which can make them difficult to 
distinguish from carcinomas (Koch et al. 2008). High grade lesions also have large areas of 
hemorrhage. There is no clinical or survival advantage between low- and high-grade 
lesions. Definitive diagnosis is made by biopsy and immunohistochemistry with antibodies 
against the endothelial marker CD31 and Factor VIII-related antigen. Staining with 
antibodies against von Willebrand’s factor II and CD34 may also be used to confirm a 
diagnosis of AS (Ohsawa et al. 1995). 
3.3 Differential diagnosis 
Cutaneous AS can initially be misdiagnosed as bruising, multiple different skin infections, 
and even insect bites. It is the duration and spreading of the lesion that prompts concern. 
Cutaneous AS is similar in appearance to another endothelial derived malignancy, Kaposi 
sarcoma. Kaposi sarcoma is a virus-induced cancer (Chang et al. 1994; Kemeny et al. 1996). 
Both Kaposi sarcoma and AS can be multicentric skin lesions with spindle cell pathology 
(Morgan et al. 2004; Nickoloff & Griffiths 1989). To further complicate the diagnosis, a 
percentage of Kaposi cells are CD31 positive and up to half of AS cells are positive for the 
endothelial lymph factor podoplanin by immunohistochemistry. However, only Kaposi 
sarcoma are positive for the presence of Kaposi’s sarcoma causative virus (Human Herpes 
Virus 8) by immunohistochemistry using antibodies against Latency nuclear antigen-1 
(LANA-1) or by amplifying viral DNA by PCR (reviewed in (Mesri et al. 2010; Schmid & 
Zietz 2005)). Cutaneous AS may also be confused with irregular growths of superficial 
vasculature or benign hemangiomas, mostly seen in infants (Lawley et al. 2005). These 
vascular malformations are commonly referred to as port wine stains or angel kisses. These 
may be distinguished from visceral AS by immunohistochemistry with antibodies against 
the Wilms tumor 1 transcription factor (Ge et al. 2011; Lawley et al. 2005). 
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Fig. 1. Histology of human and canine angiosarcoma. Stained with Hematoxylin and Eosin 
(a,b,e,f) or immunostained with antibodies against CD31 (c,d,g,h) both human (a, c) and 
canine  (b, d) splenic angiosarcoma as well as canine kidney angiosarcoma (e, g) show 
extensive networks of endothelial (CD31 positive) cells with multiple irregular 
anastomosing channels filled with blood. In contrast this canine cutaneous angiosarcoma (f, 
h) shows a highly vascular tumor with spindle-shaped CD31-positive endothelial cells. Bars 
= 100 micrometers. 
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The main discernible clinical sign of splenic AS is splenomegaly (Neuhauser et al. 2000; 
Thompson et al. 2005). Any known cause of spleen enlargement is a differential diagnosis 
for splenic AS. This includes but is not limited to lymphoma or infection (reviewed in (Pozo 
et al. 2009; Suzuki et al. 2010)). In addition, visceral disease often presents with vague flu-
like symptoms such as malaise and abdominal pain (Falk et al. 1993). 
Since the epithelioid AS subtype is defined by endothelial cells that have a large, round cell 
morphology similar to that of epithelial cells, AS may be confused with a carcinoma (Lin et 
al. 2010; Weiss & Enzinger 1982). However, epitheloid AS cells stain positive for CD31 and 
Factor VIII on immunohistochemistry (Fletcher et al. 1991; Lin et al. 2010). 
3.4 Prognosis and treatment 
Over the years AS treatment has changed very little. The usual treatment for primary AS is 
surgery followed by high-dose radiotherapy either alone or with doxorubicin-based 
chemotherapy. Even with such interventions survival rates are poor. In addition, there is no 
current standard of care based on disease subtype or location.  
Surgery is the mainstay for the treatment of primary AS. Surgical intervention is limited to 
local control and is not recommended for widely disseminated disease. Current guidelines 
call for total surgical resection of the tumor with wide negative margins to reduce re-
occurrence (Lahat et al. 2009; Mendenhall et al. 2006). However, the multicentric nature of 
cutaneous AS and its proximity to vital organs in visceral disease makes achieving complete 
tumor resection difficult. In a review of head and neck soft tissue sarcomas, positive 
margins were found in 50% of patients (Farhood et al. 1990).  
Survival rates after surgery alone are poor (Holden et al. 1987). While the addition of 
postoperative radiotherapy improves survival, there are drawbacks to radiation. Effective 
radiation treatment requires wide radiation fields and often doses of more than 50 Gy to 
achieve tumor control (Mark et al. 1996; Pawlik et al. 2003). Furthermore, radiotherapy is not 
recommended for radiation-induced AS (Mark et al. 1996).  
Doxorubicin is considered the most efficacious chemotherapy agent for local and metastatic 
AS but provides minimal tumor control or survival benefit. The response rate to 
doxorubicin has been reported to be 16 - 36%. In addition, doxorubicin causes long-term 
damage to the heart at cumulative total doses over 400 mg/m2 of body surface area 
(Chlebowski 1979). To reduce cardiotoxicity, doxorubicin can be encased in liposomes, 
reducing the amount of free doxorubicin (Cattel et al. 2003). Liposomal doxorubicin 
treatment of soft tissue sarcomas has equivalent activity but fewer adverse effects relative to 
free doxorubicin, and thus it is included in the current National Comprehensive Cancer 
Network guidelines for the treatment of soft tissue sarcomas (Judson et al. 2001). However, 
the lipid envelope increases doxorubicin absorption and retention by the skin. Side effects of 
liposomal doxorubicin may include dermal rash or sores on the palms and soles of the feet 
called palmar-plantar erythodysesthesia (Judson et al. 2001; Lorusso et al. 2007). The latter 
can be severe enough to require a dosage decrease, treatment interruption, or termination of 
treatment (Lorusso et al. 2007). 
Other adjuvant treatments are reported to have had minimal success. The use of taxanes 
such as paclitaxel to treat AS has increased. In a small study of 9 patients, 8 responded to 
paclitaxel (Fata et al. 1999). A 32-patient retrospective paclitaxel study documented a 62% 
response rate with one complete response. A 30-patient prospective study demonstrated a 
19% response rate after 6 months with 3 complete responses with surgery and a median 
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overall survival of 7.6 months (Penel et al. 2008). Paclitaxel did show a subtype specificity; 
the response rate in head and neck AS was 75%, while for other primary tumor locations the 
response rate was 58%. The median time to progression of head and neck disease was 9.5 
months compared with 7 months for AS of other primary sites (Schlemmer et al. 2008). In 
another study, scalp AS had a progression-free survival of 6.8 months, but only 2.8 months 
of progression free survival was documented for AS arising below the clavicle (Fury et al. 
2005). In comparison to spontaneous tumors that have a median survival expectation of 
nearly 9 months, radiation induced AS are more resistant to paclitaxel treatment and have a 
median overall survival of less than 6 months (Penel et al. 2008). Paclitaxel has also been 
used as a neoadjuvant therapy to decrease primary tumor size prior to surgery for splenic 
AS (Vakkalanka & Milhem 2010).  
4. Etiology 
4.1 Cellular origins 
The origin of AS tumor cells is still unknown. Angiosarcoma tumors are generally thought 
to arise from endothelial cells. The majority of cells stain positively for the endothelial cell 
markers: CD31, CD34, and Factor VIII-antigen. However, up to 70% of CD31 positive AS 
cells are also positive for the lymph endothelial marker podoplanin (Breiteneder-Geleff et al. 
1999). This suggests contributions of both lymph and vascular endothelium in AS. 
Alternatively, the tumor microenvironment may differentiate a population of 
undifferentiated endothelial cells to lymph or vascular-like endothelium.  
Cancer stem cells or cancer progenitor cells have been documented in a variety of tumors, 
but the presence of angiosarcoma cancer stem cells is not known. Interestingly, Wnt1 was 
recently found to be expressed and activated in AS cells. Furthermore, Wnt1 increases 
endothelial progenitor cell (EPC) proliferation and EPC-dependent angiogenesis (Gherghe 
et al. 2011). These data suggest a possible role of EPCs in AS tumorigenesis and tumor 
angiogenesis through a Wnt1 mechanism. As of yet, no study has clearly determined the 
role of EPCs in tumorigenesis, and the importance of tumor stem cells in AS tumorigenesis 
is still unknown. 
4.2 Molecular biology 
Angiosarcoma has no clearly defined causative mutation or chromosomal changes, but 
genomic abnormalities including chromosomal deletions, amplifications, and 
rearrangements, have been identified in a variety of these tumors. In general, the karyotypes 
of AS are complicated and display both clonal and non-clonal chromosomal changes. The 
breadth and variety of aberrations suggest they may represent chromosomal alterations 
from unbridled cell proliferation. The importance of these mutations or gene amplifications 
for tumorigenesis and tumor development is not known. The most common aberrations 
involve the loss of heterozygosity of chromosome 22 (Gil-Benso et al. 1994; Kindblom et al. 
1991; Quezado et al. 1998; Schuborg et al. 1998; Wong et al. 2001; Zu et al. 2001). The genes 
of both platelet-derived endothelial cell growth factor (PD-ECGF) and the tumor suppressor 
NF2 mapped to chromosome 22 (Kindblom et al. 1991) but the significance of this 
observation has not been explored. Losses of the short arm of chromosomes 4 and 7 are also 
common in AS (Wong et al. 2001). MYC amplification has been found in radiation-induced 
AS tumors that have an 8q24 gain (Guo et al. 2011).  
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The loss of tumor suppressor function likely plays an important role in AS development. 
The tumor suppressor p53 is mutated in a subset of AS tumors. In cardiac AS, mutant p53 is 
overexpressed and localizes to the nucleus (Hollstein et al. 1994; Soini et al. 1995; Zu et al. 
2001). Mutations in p53 codons 141 and 136 were identified in a small cohort of hepatic AS 
(Soini et al. 1995) and mutations in p53 codons 249 and 255 have been associated with vinyl 
chloride exposure (Hollstein et al. 1994). Other studies indicate the INK4a-ARF locus is 
frequently inactivated in liver AS independent of p53 mutations (Weihrauch et al. 2002). 
Mutations in the PTEN tumor suppressor have also been identified in hepatic AS; an exon 7 
mutation codes for a premature stop codon resulting in a nonfunctional protein (Tate et al. 
2007).  
Activating mutations in key signaling molecules promote AS tumorigenesis. K-Ras2 
mutations have been associated with AS (Marion 2005; Przygodzki et al. 1997) and have 
been detected in hepatic AS after exposure to vinyl chloride (Weihrauch et al. 2002). Ten 
percent of AS tumors showed activating KDR (VEGFR2) mutations (Antonescu et al. 2009). 
Also, 25% of a 20 patient study of radiation-induced AS showed a co-amplification of FLT4 
(VEGFR3) and MYC (Guo et al. 2011).  
Interestingly, vascular endothelial specific cadherin (VE-cadherin) is absent or decreased in 
AS (Martin-Padura et al. 1995; Tanioka et al. 2001; Zanetta et al. 2005). Loss of VE-cadherin 
may promote AS growth in several ways. Like other cadherins, VE-cadherin interacts with 
and retains β-catenin at adherens junctions. Through this mechanism, cadherins indirectly 
control the free (cytoplasmic) pool of β-catenin. Free β-catenin can be transported to the 
nucleus to regulate transcription. Thus, loss of VE-cadherin may represent a pathway to 
induce cancer gene dysregulation. Retention of β-catenin at adherens junctions by VE-
cadherin has been inversely correlated with vascular tumor growth and hemorrhage 
(Zanetta et al. 2005). During angiogenesis, endothelial cells detach and invade surrounding 
tissue, where they replicate and branch into a vascular network. The loss of VE-cadherin 
may facilitate angiogenesis. In addition, change in the cadherin profile of cells, or cadherin 
switching, has been implicated in tumor cell invasion and metastasis (reviewed in Maeda et 
al. (2005)). Whether cadherin misregulation in AS cells explains the invasive and metastatic 
nature of AS is not known. 
5. Insight from other sources 
The rarity of angiosarcoma has restricted the scope of basic and clinical research on this 
disease. In this section we will discuss experimental models for generating further insight 
into the biology and treatment of AS, including the study of more common (but related) 
human tumors, genetically engineered or chemically induced mouse models, and the 
emerging relevance of studies of naturally occurring AS in companion dogs. 
5.1 Related tumors in humans 
5.1.1 Kaposi sarcoma 
The similarity between Kaposi sarcoma (KS) and AS may provide a foundation for 
understanding pathways vital for AS tumorigenesis and development. Like AS, KS is an 
endothelial cell-derived tumor, but Kaposi is derived from lymphatic endothelial cells. 
Kaposi sarcoma is a vascular tumor characterized histologically by a high degree of 
angiogenesis and the presence of proliferating spindle cells (Brash & Bale 2001). The spindle 
cells act in a paracrine fashion, releasing pro-inflammatory and angiogenic factors, 
www.intechopen.com
 
Clinical and Molecular Biology of Angiosarcoma 
 
157 
including VEGF, which are necessary to promote KS lesions. Kaposi sarcoma is caused by 
human herpes virus 8 (HHV8 or KSHV; (Ablashi et al. 2002; Chang et al. 1994)). The 
expression of a single viral gene encoding a constitutively active G-protein coupled receptor 
(vGPCR) in endothelial cells is sufficient to induce angioproliferative tumors in mice that 
closely resemble human KS (Montaner et al. 2003). Among other functions, Kaposi sarcoma 
vGPCR has been demonstrated to activate the mitogen- and stress-activated protein kinases 
MAPK1/2 and p38 MAPK in a variety of cell lines (Arvanitakis et al. 1997; Bais et al. 1998; 
Burger et al. 1999; Cannon et al. 2003; Cannon & Cesarman 2004; Sodhi et al. 2000). 
Significantly, KS vGPCR-induced expression of VEGF depends upon increased activity of 
both MAPK1/2 and p38 MAPK (Bais et al. 1998; Sodhi et al. 2000). Since these are direct 
downstream targets of mitogen activated protein kinase kinases (MKKs) (Lewis et al. 1998), 
MKKs present an attractive potential therapeutic target for treatment of AS. In support of 
this we have observed that when mouse endothelial cell tumor xenografts expressing 
vGPCR are treated with a proteolytic inhibitor of MKK tumor growth is blocked and 
vascularization is decreased (Depeille et al. 2007). MEK inhibitors tested in clinical trials for 
a variety of tumors, most notably melanoma, have not shown marked efficacy (Lee & 
Duesbery 2010). However, these drugs target only MEK1 and 2, leaving other MKK 
signaling pathways intact. 
The similarity between Kaposi sarcoma and AS raises interesting questions regarding the 
etiology and molecular biology of AS. Are there spindle cell equivalents in AS that release 
cytokines and drive tumor growth?  Could AS also have a viral origin?  Indeed, several 
other human cutaneous cancers have viral origins (e.g. Merkel cell carcinoma and 
polyomavirus, squamous cell carcinoma and HPV) and viruses can cause AS in mouse 
models (see below). Moreover, similar to iatrogenic KS, cases of AS have been reported to 
develop in kidney transplant patients taking immune suppressants (e.g. Farag et al. (2005) 
and references therein). Evidence for a viral origin of AS has been sought through detection 
of HHV8 viral expression sequences. However, an initial report showing evidence of an 
HHV8 sequence in a subset of AS (McDonagh et al. 1996) was contradicted by subsequent 
studies (Lasota & Miettinen 1999). Though it appears HHV8 does not play a role in the 
origin of AS,  we can not yet rule out a viral contribution to AS tumorigenesis. 
5.1.2 Hemangioma 
Hemangiomas are benign growths arising from vascular endothelial cells. In hemangiomas, 
endothelial cells form a tortuous network of blood vessels. These lesions are common in 
newborns as strawberry patches or port wine stains. The causative mechanism of growth is 
unknown, but serum levels of VEGFA and HIF-1alpha are elevated in children with 
hemangiomas (Kleinman et al. 2007) suggesting hypoxic signals may be driving AS growth. 
Hemangiomas have been successfully treated with the beta-blocking agent propranolol 
(Leaute-Labreze et al. 2008; Sans et al. 2009). While the mechanism of action is not known, 
Sans et al. (2009) speculate that propranolol inhibits beta-adrenergic receptors expressed in 
endothelial cells, and in this manner down-regulates MAPK signaling and VEGF release.  
5.2 Similar tumors in other species 
The incidence of AS has been documented in a variety of species. For discussion purposes 
we have separated these into 1) genetically engineered or chemically induced AS models 
and 2) spontaneous or naturally occurring AS. 
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5.2.1 Induced angiosarcoma 
Mice develop AS in response to a viral infection, toxicologic treatment, or genetic 
manipulation. Study of the common properties or convergent signaling of these diverse 
agents may reveal a unified mechanism for AS induction. 
Viral Infection – Injection of Moloney mouse sarcoma virus (Stoica et al. 1990; Yuen et al. 
1991), Harvey Sarcoma virus (Chesterman et al. 1966; Harvey 1964), or Kirsten Sarcoma 
virus (Pitts et al. 1983) into mice or rats induces the formation of angiomatous lesions 
resembling angiosarcoma or Kaposi’s sarcoma. These viruses encode mutant, oncogenic 
forms of cellular oncogenes encoding c-Mos, H-Ras, and K-Ras, respectively. Each of these 
genes stimulates cellular proliferation and oncogenic transformation by activation of the 
mitogen-activated protein kinase (MAPK) signaling pathway.  
Toxicologic treatment – Rodent bioassays have been used to identify several carcinogenic 
compounds capable of inducing angiosarcoma (reviewed by Cohen et al. (2009)). Some of 
these compounds react with DNA, acting in a manner similar to vinyl chloride or 
Thorotrast. Others, such as 2-butoxyethanol, are non-genotoxic and act indirectly through 
production of reactive oxygen species and cytokines to stimulate endothelial cell 
proliferation (Corthals et al. 2006; Kamendulis et al. 2010; Klaunig & Kamendulis 2005).  
Genetic manipulations – Mice engineered to express knock-in mutations (D1226N or 
Y1228C) in the activation loop of Met develop a high incidence of angiosarcoma with 
moderately pleiomorphic endothelial cells, cavernous blood vessels, and palisading 
epithelioid-like cells (Graveel et al. 2004). Met is a tyrosine kinase receptor for the 
hepatocyte growth factor/scatter factor and is a potent activator of the MAPK signaling 
pathway, regulating among other things the epithelial-to-mesenchymal transition and 
metastatic behavior (Birchmeier et al. 2003). There are several Met antagonists in clinical 
trials for a variety of tumors (Eder et al. 2009).  
As noted above, the loss of tumor suppressor function likely plays an important role in AS 
development. Not surprisingly then, loss of tumor suppressor function in mice induces AS 
formation. Heterozygous deletion of p53 causes a broad-based cancer predisposition in 
which 57% of mice develop a variety of sarcomas including AS (Jacks et al. 1994). The 
incidence of AS in p53-null mice is dramatically increased from 15% to 53% when mice are 
crossed to Wrnhel mice harboring homozygous deletions in the helicase domain of the Wrn 
gene (Lebel et al. 2001). Similarly, p53-null mice crossed with mice lacking alleles of Ink4d 
and/or Ink4c show as high as 75-85% incidence of angiosarcoma (Zindy et al. 2003). The 
Wrn protein interacts with p53 to promote genomic stability. The Ink4 proteins bind and 
inactivate cyclin dependent kinases, preventing cell cycle progression and maintaining cells 
in a quiescent state.  
These data show that genomic manipulation resulting in deregulation of cell cycle control 
and genomic instability in mice readily promotes endothelial cells to switch to a malignant 
phenotype. Why then do mice develop AS at such high rates in response to a viral infection, 
toxicologic treatment, or genetic manipulation?  The answer may be linked to unidentified 
hereditary factors since studies of spontaneous tumorigenesis in mice indicate mice are 
predisposed to develop AS (see below). 
5.2.2 Spontaneous tumors 
Mice have a substantially higher incidence of spontaneous AS than do humans, but the 
incidence varies by strain. In a two-year study of approximately 2000 B6C3F1 mice, Haseman 
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et al. (1998) noted that  2.5-2.7% spontaneously developed AS. Although AS arose at many 
sites, the predominant locations were liver (male/female; 0.7/1.1%), spleen (0.7/1.0%), and 
uterus (0.4%). Similarly, a second study of B6C3F1 mice (Chandra & Frith 1992) noted 
4.5/1.0% (male/female) of mice spontaneously developed AS. In contrast CD-1 and Icr:Ha 
mice have spontaneous rates of AS around 0.7% and 0.4%, respectively (Chandra & Frith 
1992; Eaton et al. 1980). The increased incidence in B6C3F1 mice indicates that certain strains 
are genetically predisposed to develop AS.  
Naturally occurring (spontaneous) AS are not restricted to humans and mice. They have 
been detected in a variety of animals including rhesus macaques (Mejia et al. 2009; Myers et 
al. 2001), horses (Schultheiss 2004), cows (Sutton & McLennan 1982), ferrets (Schultheiss 
2004), dogs (Hargis et al. 1992), cats (Miller et al. 1992), rats (Schultheiss 2004), and snakes 
(Tuttle 2006). Any of these animals could potentially serve as a surrogate model system for 
human disease in an experimental context but dogs seem best suited for this purpose. While 
sharing many features in common with humans as patients, dogs have a much higher 
incidence of AS and a more rapid time course of disease progression. The canine model also 
offers some unique, advantageous features distinguishing it from other animal models and 
opening novel experimental opportunities. First, because of selective breeding, genetic 
variation within canine breeds is very low. Second, since each breed is derived from a small 
group of founders, most tracing back approximately 150 years, many of the genes associated 
with polygenic traits are fixed, so only a few variable genes determine phenotype. This 
means that it will be much easier to identify genetic disease determinants in dogs than in 
humans. Finally, companion dogs share the same environmental exposures as humans and 
thus may more accurately reflect the human condition. The ability to identify, recruit, and 
study cancers within a breed of dog offers new avenues of hope for research into clinical 
oncology and the underlying causes of AS (Gordon et al. 2009; Paoloni & Khanna 2008).  
6. Canine AS 
In contrast to AS in humans, AS is relatively common in dogs, with an overall incidence of 
24/100,000 (Dobson et al. 2002). There is substantial variability in the incidence of canine 
angiosarcoma (cAS, more commonly referred to as hemangiosarcoma) among breeds, with 
large breed dogs such as Golden retrievers and German shepherds having a much higher 
incidence. A health survey of Golden retrievers attributed 62% of all deaths to cancer, with 
cAS representing 16% of reported cancers (Glickman et al. 1999). Why this  tumor is more 
common in dogs than in humans is uncertain. It is possible that disease-causing genes were 
over-represented in the founding populations for these dogs. Alternatively, genes 
promoting susceptibility to cAS may have been co-selected along with artificially selected 
traits in the directed evolution of these breeds. Regardless, the genetic uniformity within 
breeds offers a unique and unbiased opportunity to identify genes that cause AS. 
6.1 Presentation and diagnosis 
cAS may present in virtually any tissue of the body, including bone, kidney, skeletal muscle, 
liver, lung, aorta, urinary bladder, intestine, oral mucosa, tongue, prostate, vulva/vagina, 
perineum and the cornea, nictitans or conjunctival tissue of the eye (Bergman 2010; 
Bulakowski et al. 2008; Hargis et al. 1992; Schultheiss 2004; Withrow & MacEwen 1996). 
Metastasis can involve any portion of the body, including the central nervous system. While 
most dogs present with splenic or liver lesions, some breeds show elevated incidence of 
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cutaneous (Whippets, Italian greyhounds) or cardiac (Saluki) cAS (Hargis et al. 1992; 
Prymak et al. 1988; Schultheiss 2004). This demonstrates that not only do genetic factors 
influence susceptibility to cAS, but also they determine the location at which the disease will 
present. From a research perspective, it opens new avenues for discovery of the basic 
mechanisms of the origin and progression of cancer that could be translated to further our 
understanding of the etiology, pathophysiology, and treatment of AS in human patients. 
Canine AS is the most common malignancy of the spleen in dogs (Spangler & Culbertson 
1992). Middle-aged, large (> 20kg) dogs are most prone to splenic cAS. Golden retrievers, 
German shepherds, and Labrador retrievers are overrepresented, as are other large breeds 
such as Clumber spaniels. A health survey conducted by the Golden Retriever Club of 
America/Golden Retriever Foundation reported that 16% of Golden retrievers with cancer 
die from cAS at an average age of 10 years (Glickman et al. 1999). Mixed breeds are also 
commonly affected. Dogs with visceral cAS typically present acutely, with profound 
lethargy, anemia, or sudden collapse. There may be intermittent, nonspecific clinical signs 
such as inappetance, weight loss and occasional episodes of weakness. Hemoperitoneum 
most often leads to diagnosis, often on an emergency basis.  
Splenic tumor size varies, but the lesions are frequently very large and multinodular, with 
one to many saccular, blood filled lesions. The tissue is extremely friable, which often leads 
to spontaneous rupture. It is the acute loss of blood which causes the presenting signs. Dogs 
may recover from intra-abdominal hemorrhage through resorption of the blood 
(autotransfusion) and erythrocyte regeneration. However, there will frequently be further 
hemorrhaging. Anecdotally, more dogs are lost to euthanasia than to spontaneous 
hemorrhage, as the owners do not wish their dogs to suffer further such episodes.  
In contrast to humans, in whom left atrial AS is more frequent (Casha et al. 2002), cardiac 
cAS most commonly occurs in the right atrium and dogs of the Saluki breed are particularly 
prone to development of such tumors. Right atrial cAS is also seen in Golden retrievers and 
German shepherd dogs. Cardiac cAS can be devastating from the outset, with many dogs 
presenting for cardiac tamponade and signs of right heart failure. The pressure of blood 
from a ruptured cAS in the right atrium (RA) fills the pericardial sac and leads to extreme 
respiratory distress, anxiety, and collapse. Alternatively, dogs may simply die acutely from 
cardiac arrest, and the disease is discovered upon necropsy of what seemed to be an 
otherwise healthy dog. Many cases are likely never conclusively diagnosed, as necropsy is 
infrequent in veterinary medicine.  
Cardiac cAS are typically red to dark red or purple in color, and ranging from millimeters to 
centimeters in length. Such tumors are prone to spontaneous hemorrhage, which may lead 
to pericardial effusion and cardiac tamponade. While no definitive studies have delineated 
time course for these tumors, anecdotal reports suggest progression may be very rapid. 
Cardiac cAS can occur with or without splenic involvement and is more likely to present as 
a solitary lesion in some breeds such as the Saluki. It has not been determined if right atrial 
involvement is a primary tumor site or reflects a site of metastasis when concurrent visceral 
disease is present.  
As in human AS, cutaneous cAS most often presents as solitary or multiple small dermal 
masses, which can extend into the subcutis or even into underlying musculature. They are 
frequently seen on non-haired skin on the ventral abdomen of light-colored dogs (Italian 
greyhounds, whippets, Dalmatians, pit bulls), especially when those dogs have excess 
exposure to solar radiation (southern latitudes, tendency towards sunbathing). Cutaneous 
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cAS may also occur on haired skin of darker colored dogs. Solar elastoses has been 
associated with cutaneous cAS in a large retrospective study involving many dogs from 
California practices (Hargis et al. 1992). A more recent retrospective study conducted at the 
University of Colorado did not confirm this finding (Schultheiss 2004), but the patient 
population for this study may have been comprised of more dogs from northern latitudes. 
The geographic location of the patients themselves was not annotated in either of these 
studies.  
The small, solitary or multiple dermal lesions of cutaneous cAS are often less than 1 cm in 
diameter, but may exceed 3 cm (Hargis et al. 1992). Mitotic figures are usually seen in 
malignant cAS. Conclusive diagnosis is always via histopathology, regardless of tumor 
location. Several markers can be used (e.g. CD31, factor VIII, Claudin-5, and cardiac 
troponin) to aid in confirmation of diagnosis (Chun et al. 2010; Jakab et al. 2009; Shaw et al. 
2004; Withrow & MacEwen 1996).  
6.2 Differential diagnosis 
As in human AS, the differential diagnosis of canine AS varies with the location of the 
disease. Visceral tumors must be distinguished from other neoplasms  such as 
hemangiomas, other sarcomas, lymphoma, leiomyomas, and hematomas (Jakab et al. 2009). 
Signs of acute anemia, extreme lethargy, or collapse, requires exclusion of immune mediated 
hemolytic anemia (IMHA),  trauma, coagulopathy, toxin exposure and allergic reaction. One 
retrospective study reported that among anemic dogs presenting with a splenic mass and 
abdominal bleeding requiring transfusion, 70% had splenic cAS (Hammond & Pesillo-
Crosby 2008). Conclusive diagnosis of cAS requires histopathology of the excised tissue.  
Cardiac cAS must also be differentiated from other tumors and from idiopathic pericarditis 
(IP), both of which can cause pericardial effusion. In one retrospective study conducted in 
the UK, dogs with cardiac masses detected by ultrasound (echo-positive) had significantly 
shorter survival times than echo-negative dogs (Johnson 2004). Patients with a discernible 
cardiac mass, ascites, or collapse had a much less favorable prognosis than patients with IP. 
Another retrospective study reported that dogs with right atrial cAS treated surgically by 
pericardectomy and chemotherapy had a mean survival time of 164 days, compared to 46 
days for dogs treated by pericardectomy alone (Weisse et al. 2005). However, this report also 
noted that dogs receiving chemotherapy were significantly younger and had significantly 
lower white blood cell counts than the dogs that did not receive chemotherapy, so case 
collection bias was a concern.  
Cutaneous cAS must be differentiated from other cutaneous tumors, nevi, and cysts. 
Histopathology is the only conclusive method of diagnosis. Because dogs may suffer from 
hemangiomas as well as hemangiosarcomas, and because depth of invasion can be a 
prognostic indicator, it is recommended that all tumors be submitted for histopathologic 
examination and confirmation of clear surgical margins.  
6.3 Prognosis and treatment 
The behavior of cAS is also linked to the site of origin, with visceral lesions being more 
aggressive than cutaneous lesions (Schultheiss 2004). For visceral disease, the high rate of 
early metastasis and the lack of early clinical signs or hematologic changes lead to late 
diagnosis and extremely poor prognosis. The average life span upon diagnosis of splenic 
cAS is less than three months for dogs treated with splenectomy alone (Spangler & 
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Culbertson 1992). Dogs treated with adjunctive chemotherapy (usually doxorubicin-based 
protocols) average less than six months survival (Kim et al. 2007; Sorenmo et al. 2004). 
Owners frequently elect to euthanize the dog at the time of diagnosis or shortly thereafter.  
Cardiac cAS is equally grim, with many dogs dying of acute cardiac arrest prior to any overt 
clinical signs. This sudden death syndrome is seen particularly among Saluki. Dogs may 
appear clinically normal and sometimes die in their sleep. Others may develop exercise 
intolerance, weakness, lethargy, and inappetance prior to developing ascites secondary to 
cardiac tamponade. One retrospective study of 23 cases of right atrial cAS treated surgically, 
with or without chemotherapy, reported a mean survival time of 175 days or 42 days, 
respectively (Weisse et al. 2005). Another retrospective study from  the UK which evaluated 
dogs with pericardial effusion reported a mean survival time of 26 days for dogs with 
echocardiograms revealing a cardiac mass versus 1068 days for those with effusion but no 
detectable mass. However, in this study, no dogs with detectable masses had treatment 
beyond pericardiocentesis, and many were euthanized at diagnosis (Johnson 2004).  
In stark contrast is the positive prognosis for cutaneous cAS. A majority of dogs with strictly 
cutaneous cAS survive many years with local recurrent disease (Schultheiss 2004). 
Schultheiss reported that complete surgical resection of cutaneous cAS was the most 
important prognostic factor for survival (Schultheiss 2004). A retrospective study of 25 dogs 
reported that those with cutaneous cAS confined to the dermis had a mean survival time of 
780 days, compared with 172 and 307 days for dogs with a primary tumor involving the 
hypodermis or underlying muscle, respectively (Ward et al. 1994). Confinement to the 
dermis also was correlated with better outcome, most likely due to complete surgical 
resection (Schultheiss 2004).  
The response of cAS tumors to treatment varies greatly depending on the site of the tumor. 
Dogs with splenic tumors survive a few months beyond splenectomy but live longer than 
those that do not have surgery. Survival time is measured in months regardless of 
treatment, but owners frequently elect splenectomy for palliative care, extension of quality 
time, and reduction of the worry regarding continued intra-abdominal hemorrhage. The 
addition of doxorubicin-based chemotherapy protocols may add a few more months of 
survival. Single agent doxorubicin, administered intravenously every three weeks for up to 
five cycles is commonly used if chemotherapy is elected. Alternate protocols include 
doxorubicin plus cyclophosphamide, or doxorubicin, vincristine and cyclosphosphamide. 
No protocol is superior. Doxorubicin can induce dose-dependent cardiotoxicities in dogs; 
the total cumulative dose should not exceed 180-240 mg/m2. A study evaluating the 
potential use of epirubicin in splenectomized cAS patients reported no cardiac toxicity (Kim 
et al. 2007). However, gastrointestinal side effects occurred in a majority of the patients, and 
neutropenia was also common. The expense of this treatment may also preclude this drug 
from becoming more commonly used, although it may provide an option for dogs with 
preexisting cardiac disease (Kim et al. 2007). 
Cutaneous cAS is generally treated with complete surgical excision. There are minimal long-
term consequences apart from the necessity of multiple surgeries often being required. This 
is not generally due to recurrence of excised tumors; rather, patients tend to develop tumors 
spontaneously in multiple sites. It is unclear whether these represent new primary tumors 
or metastatic disease (Hargis et al. 1992; Ward et al. 1994). Multiple surgeries can create a 
financial hardship for the owner, and may be the cause for dogs to be relinquished to rescue 
organizations or euthanized.  
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6.4 Cell and molecular biology 
Molecular insight into cAS is limited and focuses primarily on visceral disease, but what is 
known is consistent with the biology of human AS. Tumor-derived cell lines and cell isolates 
express endothelial and hematopoietic stem cell markers, suggesting they may arise from 
pluripotent bone marrow-derived stem cells and/or cells committed to the endothelial 
lineage (Fosmire et al. 2004; Lamerato-Kozicki et al. 2006; Tamburini BA 2010; Thamm et al. 
2006). Cells form branching vascular structures when grown on Matrigel (Thamm et al. 
2006), secrete pro-angiogenic factors including VEGF and bFGF , and express elevated levels 
of Ang-1 and Ang-2 mRNA (Kato et al. 2006). Upon injection into immune-compromised 
mice, such cells readily form AS-like tumors expressing endothelial markers including 
CD31, vWF, VEGF-A, bFGF, flt-1, flk-1, FGFR-1, HoxA9, HoxB3, HoxB7, HoxD3, Pbx1, and 
Meis1 (Kodama et al. 2009). Although mutations in p53 have not been detected, cAS stain 
positively for nuclear p53 (Yonemaru et al. 2007). As in the human disease, cAS lesions have 
been found to harbor point mutations or deletions in the C-terminal domain of PTEN  
(Dickerson et al. 2005). 
7. Conclusions 
The rarity of angiosarcoma has had a profound impact on its clinical management and 
research. Most clinicians are unfamiliar with this disease and thus do not have experience to 
guide management decisions. Much of the literature regarding these rare tumors is 
comprised of anecdotal case reports or retrospective analyses which are difficult to 
assimilate and interpret. Thus, we must be especially wary not to assume all AS are 
equivalent. The varied morphology and presentation of these lesions indicates we may be 
dealing with not one, but several diseases with unique physiologic or clinical properties and 
pharmacologic responsiveness. For instance, it has been reported that tumor behavior might 
depend on the site of origin, with superficial tumors associating with a longer progression-
free survival after initial treatment (Fury et al. 2005; Schlemmer et al. 2008). However, it is 
unclear whether this is caused by intrinsic biologic differences or differences in clinical 
presentation and prior treatment. Unfortunately, when AS is examined prospectively in 
clinical trials it is usually included as a limited number of cases within a larger study of 
various soft-tissue sarcomas. Further progress in our understanding of the biology and 
treatment of AS depends on the willingness of the medical research and clinical oncology 
communities to share resources through multi-center collaborations. In the absence of such 
efforts, alternative strategies are needed to generate meaningful insight into this disease.  
Significant insight into the biology of AS has been generated through translational studies of 
related human tumors and mouse models. Collectively, studies of Kaposi sarcoma and 
hemangiomas, plus studies conducted in mouse models provide strong support for the 
hypothesis that MAPK signaling is a key event in the induction of endothelial cell 
proliferation and AS in mice and humans. This pathway has been invoked to explain the 
origins of many other tumor types. MAPK signaling pathways are frequently activated in 
endothelial cells during developmental and pathologic angiogenesis (reviewed in (Depeille 
et al. 2007)). Further, MAPK signaling is physiologically activated in response to shear stress 
(Azuma et al. 2000) and in pre-atherosclerotic plaques (Muslin 2008). A key question that 
needs to be addressed may therefore be not how these events trigger AS, but why they do 
not trigger AS more frequently. An examination of the role of MAPK phosphatases in 
endothelial cells and in AS tumorigenesis  may be instructive.  
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However, important questions remain to be asked and answered. What are the key 
biochemical pathways involved in this disease?  Does misregulation of MAPK signaling by 
phosphatases allow constitutive signaling to promote tumorigenesis?  Do genetic mutations 
contribute to or establish a microenvironment that predisposes scalp, spleen, liver, or heart 
to develop AS?  Why is angiosarcoma infrequent in humans, while it is more prevalent in 
dogs?  Can we identify molecular targets for drug therapies?  Can we devise a fundable and 
meaningful clinical trial to test novel therapies for such a rare disease?  Will the use of 
spontaneous animal tumor models prove useful in informing human clinical trials? 
The canine model is of growing interest in this regard since it closely resembles human 
disease. Studies of spontaneous cAS offer a clear experimental advantage through genome-
wide association studies of single nucleotide polymorphisms that provide an unbiased 
approach to identify the genes contributing to the onset and progression of disease in a 
compressed time frame. This, combined with the availability of tumor material and the 
presence of multi-institution consortia such as the Canine Comparative Oncology and 
Genomics Consortium, the LUPA consortium, the Canine Hereditary Cancer Consortium, 
and the Canine Oncology Trials Consortium, may facilitate rapid identification and 
translation of novel therapies through clinical trials that may benefit dogs and humans alike. 
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